EXEL Insider Trading
EXELIXIS, INC. | Biological Products, (No Diagnostic Substances)
Comprehensive Trading Performance Summary
The investment history of corporate insiders at EXELIXIS, INC. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Biological Products, (No Diagnostic Substances) sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-26 02:32 | 2024-09-23 | Hessekiel Jeffrey | Officer - EVP & General Counsel | SELL | $26.38 | 25,000 | $659,500 | 605,325 | -4.0% |
| 2024-08-29 02:07 | 2024-08-26 | Hessekiel Jeffrey | Officer - EVP, General Counsel & Sec | OPT+S | $25.79 | 20,000 | $515,800 | 630,325 | 0.0% |
| 2024-08-17 02:35 | 2024-08-14 | Freire Maria C | Director | SELL | $26.56 | 8,250 | $219,120 | 91,007 | -8.3% |
| 2024-08-15 02:12 | 2024-08-12 | Aftab Dana | Officer - CSO/EVP Disc & Trans Research | SELL | $27.06 | 20,883 | $565,094 | 500,107 | -4.0% |
| 2024-08-13 02:22 | 2024-08-08 | POSTE GEORGE | Director | SELL | $26.89 | 33,725 | $906,865 | 199,020 | -14.5% |
| 2024-08-10 02:32 | 2024-08-07 | Aftab Dana | Officer - CSO/EVP Disc & Trans Research | OPT+S | $25.00 | 95,000 | $2,375,000 | 520,990 | 0.0% |
| 2024-08-10 02:32 | 2024-08-07 | Haley Patrick J. | Officer - EVP, Commercial | SELL | $25.50 | 14,000 | $357,000 | 341,036 | -3.9% |
| 2024-08-10 02:31 | 2024-08-09 | Senner Christopher J. | Officer - EVP and CFO | OPT+S | $27.19 | 125,000 | $3,398,750 | 721,680 | 0.0% |
| 2024-08-10 02:32 | 2024-08-07 | Hessekiel Jeffrey | Officer - EVP, General Counsel & Sec | OPT+S | $25.97 | 80,000 | $2,077,600 | 630,325 | 0.0% |
| 2024-06-07 03:37 | 2024-06-04 | WYSZOMIERSKI JACK L | Director | SELL | $22.00 | 8,287 | $182,314 | 349,499 | -2.3% |
| 2024-05-31 02:50 | 2024-05-28 | JOHNSON DAVID EDWARD | Director | BUY | $20.55 | 425,000 | $8,733,963 | 1,525,730 | +38.6% |
| 2024-05-24 01:55 | 2024-05-21 | Smith Julie | Director | SELL | $21.12 | 27,280 | $576,154 | 5,445 | -83.4% |
| 2024-05-23 02:23 | 2024-05-20 | PAPADOPOULOS STELIOS | Director | OPT+S | $21.00 | 11,437 | $240,177 | 1,260,578 | 0.0% |
| 2024-05-23 02:23 | 2024-05-21 | POSTE GEORGE | Director | OPT+S | $20.96 | 11,686 | $244,939 | 213,907 | 0.0% |
| 2024-05-16 02:44 | 2024-05-13 | WYSZOMIERSKI JACK L | Director | OPT+S | $21.37 | 10,923 | $233,425 | 338,948 | 0.0% |
| 2024-03-26 02:31 | 2024-03-21 | Garber Alan M | Director | OPT+S | $24.01 | 19,205 | $461,112 | 35,703 | 0.0% |
| 2024-02-28 02:58 | 2024-02-23 | Haley Patrick J. | Officer - EVP, Commercial | SELL | $21.45 | 47,020 | $1,008,579 | 384,866 | -10.9% |
| 2024-02-23 01:08 | 2024-02-21 | JOHNSON DAVID EDWARD | Director | BUY | $20.70 | 190,000 | $3,932,734 | 1,100,730 | +20.9% |
| 2023-12-15 03:56 | 2023-12-12 | Haley Patrick J. | Officer - EVP, Commercial | OPT+S | $23.16 | 64,149 | $1,485,851 | 307,687 | 0.0% |
| 2023-12-15 03:55 | 2023-12-13 | Hessekiel Jeffrey | Officer - EVP, General Counsel & Sec | SELL | $23.01 | 25,000 | $575,250 | 533,345 | -4.5% |
| 2023-12-05 02:22 | 2023-11-30 | Hessekiel Jeffrey | Officer - EVP, General Counsel & Sec | SELL | $22.04 | 50,000 | $1,101,750 | 558,345 | -8.2% |
| 2023-11-30 00:30 | 2023-11-27 | JOHNSON DAVID EDWARD | Director | BUY | $21.61 | 120,409 | $2,602,038 | 910,730 | +15.2% |
| 2023-11-30 00:30 | 2023-11-27 | JOHNSON DAVID EDWARD | Director | SELL | $21.61 | 120,409 | $2,602,038 | 790,321 | -13.2% |
| 2023-09-02 03:15 | 2023-08-30 | Aftab Dana | Officer - CSO/EVP Disc & Trans Research | SELL | $22.47 | 4,600 | $103,362 | 399,943 | -1.1% |
| 2023-08-08 03:24 | 2023-08-03 | Haley Patrick J. | Officer - EVP, Commercial | SELL | $20.67 | 30,553 | $631,531 | 285,467 | -9.7% |
| 2023-08-08 04:20 | 2023-08-03 | Senner Christopher J. | Officer - EVP and CFO | OPT+S | $20.60 | 120,000 | $2,471,400 | 571,631 | 0.0% |
| 2023-08-04 03:02 | 2023-08-01 | Hessekiel Jeffrey | Officer - EVP, General Counsel & Sec | OPT+S | $19.63 | 55,710 | $1,093,587 | 571,976 | 0.0% |
| 2023-04-06 03:57 | 2023-04-05 | Hessekiel Jeffrey | Officer - EVP, General Counsel & Sec | OPT+S | $20.01 | 38,930 | $778,989 | 582,435 | 0.0% |
| 2023-03-15 03:22 | 2023-03-10 | WYSZOMIERSKI JACK L | Director | OPT+S | $16.61 | 15,300 | $254,133 | 317,467 | 0.0% |
| 2023-03-04 03:59 | 2023-03-01 | Hessekiel Jeffrey | Officer - EVP, General Counsel & Sec | OPT+S | $17.13 | 77,860 | $1,333,742 | 527,716 | 0.0% |
| 2023-03-02 03:56 | 2023-02-27 | Aftab Dana | Officer - CSO/EVP Disc & Trans Research | OPT+S | $17.50 | 82,500 | $1,443,750 | 351,472 | 0.0% |
| 2023-02-24 05:08 | 2023-02-21 | Garber Alan M | Director | OPT+S | $17.49 | 40,000 | $699,600 | 31,417 | 0.0% |
| 2023-02-11 03:56 | 2023-02-09 | FELDBAUM CARL B | Director | OPT+S | $17.78 | 40,000 | $711,200 | 18,701 | 0.0% |
| 2023-02-09 04:17 | 2023-02-06 | Haley Patrick J. | Officer - EVP, Commercial | OPT+S | $17.37 | 25,000 | $434,250 | 254,414 | 0.0% |
| 2022-12-17 04:09 | 2022-12-15 | Lamb Peter | Officer - EVP, Scientific Strategy & CSO | OPT+S | $15.88 | 20,000 | $317,600 | 410,958 | 0.0% |
| 2022-12-02 04:11 | 2022-11-29 | POSTE GEORGE | Director | OPT+S | $16.68 | 40,000 | $667,200 | 193,189 | 0.0% |
| 2022-11-18 04:46 | 2021-05-17 | Hessekiel Jeffrey | Officer - EVP, General Counsel & Sec | SELL | $22.73 | 36,000 | $818,280 | 586,822 | -5.8% |
| 2022-09-15 02:57 | 2022-09-12 | Haley Patrick J. | Officer - EVP, Commercial | OPT+S | $17.94 | 40,000 | $717,600 | 261,591 | 0.0% |
| 2022-06-02 03:28 | 2022-05-27 | Haley Patrick J. | Officer - EVP, Commercial | SELL | $18.21 | 18,812 | $342,567 | 239,818 | -7.3% |
| 2022-05-14 03:10 | 2022-05-12 | WILLSEY LANCE | Director | OPT+S | $19.65 | 40,000 | $786,000 | 424,415 | 0.0% |
| 2022-04-07 03:08 | 2022-04-04 | WYSZOMIERSKI JACK L | Director | OPT+S | $23.00 | 6,696 | $154,008 | 273,192 | 0.0% |
| 2022-04-05 03:11 | 2022-03-31 | Haley Patrick J. | Officer - EVP, Commercial | OPT+S | $22.72 | 20,000 | $454,300 | 269,191 | 0.0% |
| 2022-03-31 03:17 | 2022-03-28 | Hessekiel Jeffrey | Officer - EVP, General Counsel & Sec | SELL | $22.00 | 18,000 | $396,000 | 605,236 | -2.9% |
| 2022-03-04 04:07 | 2022-03-01 | Garber Alan M | Director | OPT+S | $21.00 | 21,301 | $447,321 | 31,417 | 0.0% |
| 2022-03-01 04:09 | 2022-02-25 | Haley Patrick J. | Officer - EVP, Commercial | SELL | $19.53 | 31,238 | $610,078 | 198,476 | -13.6% |
| 2022-03-01 04:11 | 2022-02-24 | Hessekiel Jeffrey | Officer - EVP and General Counsel | SELL | $20.00 | 18,000 | $360,000 | 555,361 | -3.1% |
| 2022-02-25 04:20 | 2022-02-22 | FELDBAUM CARL B | Director | OPT+S | $19.49 | 20,000 | $389,800 | 8,521 | 0.0% |
| 2022-02-25 04:22 | 2022-02-22 | PAPADOPOULOS STELIOS | Director | SELL | $19.56 | 84,515 | $1,653,113 | 1,220,036 | -6.5% |
| 2022-02-05 05:52 | 2022-02-03 | Haley Patrick J. | Officer - EVP, Commercial | OPT+S | $17.91 | 60,000 | $1,074,600 | 245,241 | 0.0% |
| 2021-12-18 04:35 | 2021-12-15 | Lamb Peter | Officer - EVP, Scientific Strategy & CSO | OPT+S | $17.44 | 47,500 | $828,400 | 363,172 | 0.0% |
How to Interpret $EXEL Trades
Not every insider transaction in EXELIXIS, INC. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $EXEL shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for EXEL
Insider activity data for EXELIXIS, INC. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $EXEL, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.